【新型コロナ】興和のイベルメクチン治験 終了予定を2022年9月から12月に延期
A Phase III Confirmatory Study of K-237
Last Update Posted : July 1, 2022
Primary Completion: September 30 → December 31, 2022 [Anticipated]
Study Completion: September 30 → December 31, 2022 [Anticipated]
Drug: K-237 0.3-0.4mg/kg (once daily)